EUVIMEDEUVIMED entdecken
Crossref

Discovery of Quinoline-Based Highly Potent and Selective THRβ Agonists for MASLD Treatment

Kean Wang, Lixin Gao, Feiyang Chen, Tao Yin, Dandan Sun, Yi Zang, Hong Liu, Jia Li, Jiang Wang

Journal of Medicinal Chemistry · 05.11.2026

DOI: 10.1021/acs.jmedchem.6c02885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.11.2026. Verfasst von Kean Wang und 8 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction-associated steatohepatitis (MASH) is a progressive metabolic liver disease lacking sufficient clinical therapies. Thyroid hormone receptor β (THRβ), a liver-enriched nuclear receptor, is an attractive therapeutic target. Resmetirom, the first FDA-approved THRβ agonist for MASH, achieves clinical efficacy yet suffers from suboptimal THRβ/THRα selectivity restricting its therapeutic window. We used a scaffold-hopping strategy to design and synthesize a novel series of quinoline-based THRβ agonists. Systematic SAR optimization identified compound 24 as a potent, selective THRβ agonist, with an EC50 of 46.07 nM and 34.3-fold THRβ/THRα selectivity. It displayed favorable oral bioavailability (F = 54.1%) and approximately 2-fold higher hepatic exposure than Resmetirom. In animal models, compound 24 ameliorated metabolic dysfunction, reduced hepatic lipid accumulation, and suppressed liver inflammation and fibrosis. No obvious thyroid axis disruption or THRα-mediated cardiotoxicity was observed, and mice tolerated compound 24 up to 100 mg/kg. Overall, compound 24 represents a promising THRβ-selective therapeutic candidate for MASH.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Wang, K., Gao, L., Chen, F., Yin, T., Sun, D., Zang, Y., Liu, H., Li, J., & Wang, J. (2026). Discovery of Quinoline-Based Highly Potent and Selective THRβ Agonists for MASLD Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02885

Vancouver

Wang K, Gao L, Chen F, Yin T, Sun D, Zang Y, et al. Discovery of Quinoline-Based Highly Potent and Selective THRβ Agonists for MASLD Treatment. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02885

BibTeX
@article{Wang2026,
  author = {Wang, Kean and Gao, Lixin and Chen, Feiyang and Yin, Tao and Sun, Dandan and Zang, Yi and Liu, Hong and Li, Jia and Wang, Jiang},
  title = {Discovery of Quinoline-Based Highly Potent and Selective THRβ Agonists for MASLD Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02885}
}
Kostenlos starten →